“The study published in JAMA Internal Medicine on June 15, 2026, found that COVID-19 vaccination was associated with a 38% lower risk of major cardiovascular events among veterans, with broader protective effects observed in older adults and those with chronic conditions, according to Statnews.com. https://www.statnews.com/2026/06/15/covid-vaccination-cardiovascular-protection-jama-study/”
Study Reveals Broad Cardioprotective Benefits of COVID Vaccines
A large-scale study published in *JAMA Internal Medicine* on June 15, 2026, found that COVID-19 vaccination significantly reduced the risk of major cardiovascular events, including heart attacks, strokes, and deaths, among veterans. The research, led by Ziyad Al-Aly of Washington University in St. Louis, tracked over 1 million veterans who received flu vaccinations at U.S. Veterans Affairs facilities in 2024, with about a third also getting a COVID vaccine. The findings showed a 38% lower risk of COVID-associated cardiovascular events among vaccinated individuals, with the greatest benefits seen in those aged 75 and older and those with chronic kidney or lung disease.
Al-Aly emphasized that many cardiovascular events linked to SARS-CoV-2 may go unrecognized due to limited testing. “Despite the virus evolving and being perceived as less consequential, there’s still a tidal wave of SARS-CoV-2 circulating, leading to unattributed heart problems,” he said. The study also noted a 24% reduction in all-cause cardiac events, suggesting broader protective effects beyond directly documented infections.
Conflicting Data on Vaccine Efficacy in Seniors
While the *JAMA* study highlighted long-term benefits, a separate report from *Mirage News* on June 16, 2026, cited data showing 55% effectiveness of vaccines against symptomatic disease in older adults within two months of vaccination. This figure contrasts with the 38% reduction in cardiovascular events, raising questions about how different metrics define “effectiveness.” The *Mirage News* article, which focused on vaccine uptake in 2025-2026, noted that low vaccination rates among vulnerable groups created missed opportunities for preventing severe illness.
Expert Analysis: Linking Vaccines to Cardiovascular Protection
Robert Califf, a cardiologist and former FDA commissioner, commented on the *JAMA* findings, stating that vaccinations—both for COVID and other diseases—have been shown to reduce chronic disease risks, including cardiovascular issues. “There are many studies showing this isn’t inconsistent with prior findings,” he said. Califf also cautioned that the testing environment has changed, making it harder to confirm whether subsequent infections were linked to SARS-CoV-2.
Al-Aly, however, stressed that undiagnosed infections remain a critical factor. “Much of the SARS-CoV-2 circulation goes unrecognized, leading to heart problems that aren’t tied to the virus,” he explained. The study’s authors estimated that the observed benefits could prevent 3,500 major cardiac events and 2,400 deaths annually per 1 million people.
Myocarditis Concerns and Vaccine Safety
Despite the cardioprotective benefits, the study acknowledged early concerns about vaccine-related myocarditis, particularly in young men. However, researchers noted that vaccine-induced myocarditis is generally milder than that caused by actual COVID-19 infections. This distinction highlights the complex risk-benefit profile of vaccination, with long-term cardiovascular protection offsetting short-term side effects in some populations.
Public Health Implications and Future Research
The findings underscore the evolving understanding of COVID-19’s impact beyond acute illness. Al-Aly noted that “unrecognized infections continue to drive heart problems,” suggesting that broader vaccination efforts could mitigate this hidden burden. Califf, meanwhile, called for large-scale randomized trials to clarify the long-term effects of vaccination, stating, “I thought the new NIH was going to answer these questions, but it doesn’t seem to be doing that.”
What’s Next for Vaccine Policy?
Public health officials face the challenge of balancing vaccine uptake with evolving perceptions of COVID-19 risk. The *Mirage News* report highlighted that while vaccines showed strong short-term efficacy, low participation among seniors—despite their higher risk—remains a barrier. “More than half the population, even high-risk individuals, aren’t electing to get updated vaccines,” Califf said, emphasizing the need for clearer communication about risks and benefits.
“Over the short term, the Covid vaccines in the Wiegand study are roughly as effective as flu vaccines,” Califf added, suggesting that public health strategies could draw parallels between COVID-19 and seasonal influenza.
Conclusion: A Complex Landscape of Evidence
The dual findings from *JAMA* and *Mirage News* paint a nuanced picture of COVID-19 vaccination’s role in cardiovascular health. While the *JAMA* study underscores long-term protective effects, the *Mirage News* report highlights gaps in real-world application. As researchers continue to analyze these data, the focus will remain on reconciling these perspectives to inform future public health strategies.
“Despite the virus evolving, the risk isn’t gone,” Al-Aly said. “We need to keep testing, keep vaccinating, and keep looking for the connections we’re missing.
Find more reporting in our News section.
